(Information sent by the signatory company)

Seville, April 1

KeyZell, Spanish biopharmaceutical leader, joins BME's acceleration program, 'Pre-Market Environment', strengthening its commitment to oncology innovation

KeyZell, a Spanish biopharmaceutical company, with subsidiaries in the United Kingdom, Australia, Thailand and Mexico, is proud to announce its incorporation into the prestigious acceleration program of Spanish Stock Exchanges and Markets (BME) known as 'Pre-Market Environment' (EpM). As a leader in the development of innovative technologies to combat cancer, this partnership marks a significant step in its continued commitment to excellence and innovation in the field of oncology. Designed for companies with high growth potential, EpM offers KeyZell the opportunity to expand your network of contacts, access strategic resources and prepare for a possible entry into regulated securities markets. KeyZell's inclusion in EpM coincides with its ambitious expansion plan, which includes the upcoming initiation of clinical trials for cancer triple negative breast cancer and non-small cell lung cancer. In addition, it has recently signed an agreement with the Regional Government of Andalusia to validate its Artificial Intelligences and develop new tools for Oncological Precision Medicine. Currently, KeyZell has two artificial intelligence (AI) platforms: O.P.S. (Oncology Precision System), with an accuracy of 89%, which helps predict the best personalized treatment to guarantee the highest 5-year survival rate, and O.D.S. (Oncology Diagnostic System), an innovative tool that helps radiologists detect tumor masses with 93% accuracy and provides the diagnosis in seconds. Both platforms are in the process of ISO 13485 certification and CE Marking. KeyZell's inclusion in the EpM program underlines its continued commitment to innovation, excellence, progress in the fight against cancer and the creation of value for shareholders. About from KeyZell: KeyZell is a biopharmaceutical and deep-tech company that uses cutting-edge technologies in the biomedical sciences to transform the research and development of new medicines, as well as to develop artificial intelligence tools to fight cancer. Its ultimate goal is to improve the quality of life of patients and save lives.

Contact Contact name: Tony Solanes Contact description: KeyZell Contact phone: 34666423450